Beta Bionics, Inc. (BBNX) Stock Price & Analysis

Beta Bionics, Inc. (BBNX) closed at USD 17.85 on Wednesday, October 28, 2026, down 16.55% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 21.39; the Oct 28, 2026 session ranged USD 17.15–20.07 on volume of 2,798,372 shares. Market capitalization is $962.94M, with a 52-week range of USD 8.8–32.71 (NGM). Source: Nexqual, retrieved October 28, 2026 at 22:58 UTC.

Also available as compact Markdown for AI agents: nexqual.com/BBNX.md

Key facts (BBNX)

• Last four reported quarters (through Sep 30, 2026): revenue $127M, net income -$83.1M (-65.3% margin), free cash flow -$66.0M (SEC filings).
• Analysts: Buy (mean 2.13 on a 1–5 scale) (15 analysts), mean target USD 24.24 (range 16–30.4).
• Total return with dividends: 1Y -33.4% vs S&P 500 +13.6%; 5Y -25.0% vs S&P 500 +79.8%.
• Next earnings: 2026-10-27, EPS estimate USD -0.44, revenue estimate $30.2M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BBNX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Sep 30, 2026) (BBNX)

P/S 7.6x · P/B 2.4x · FCF yield -6.85% · Earnings yield -8.63%

Analysts (BBNX)

Consensus Buy (mean 2.13 on a 1–5 scale), 15 analysts; mean target USD 24.24 (low 16, high 30.4).

Rating changes, last 120 days:

Total return (dividends reinvested) (BBNX)

BBNX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

BBNX recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

BBNX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 24, 2026.

BBNX company outlook (results filed Oct 27, 2026)

• “(Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2026 and updated its full year guidance for the year ending December 31, 2026.”
• “Recent Strategic Highlights Announced FDA clearance of Mint™ and expectations for full U.S. commercial launch of Mint in the first quarter of 2027, with anticipated manufacturing capacity to produce at least 1.5 million total disposable units in the full year 2027.”

Quoted word-for-word from the SEC 8-K results press release.

BBNX analyst estimates and revisions

BBNX options: expected move

30-day implied volatility 74% vs 74.7% realized over the last 30 trading days. Put/call ratio (volume) 0.2. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 28, 2026 at 22:58 UTC)

Technical Analysis (BBNX)

Nexqual's technical model rates BBNX "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 28, 2026 at 22:58 UTC.

Analyst Ratings (BBNX)

Wall Street analysts rate BBNX "Buy" based on 15 analysts, with a mean price target of USD 24.24 (range USD 16–30.4), per Nexqual as of October 28, 2026 at 22:58 UTC.

Earnings (BBNX)

Recent Earnings History

Source: Nexqual, October 28, 2026 at 22:58 UTC.

Financials & Fundamentals (BBNX)

Source: Nexqual, October 28, 2026 at 22:58 UTC.

Financial Health Score (BBNX)

Nexqual rates Beta Bionics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 28, 2026 at 22:58 UTC.

Ownership (BBNX)

Source: Nexqual, October 28, 2026 at 22:58 UTC.

Leadership (BBNX)

Beta Bionics, Inc. is led by Sean T. Saint PE, President, CEO & Director, per Nexqual as of October 28, 2026 at 22:58 UTC.

Major Backers & Investors (BBNX)

Notable institutional backers of Beta Bionics, Inc. include Eventide Asset Management LLC, MUTUAL FUND SERIES TRUST-Eventide Gilead Fund, Soleus Capital Management, L.P., according to Nexqual as of October 28, 2026 at 22:58 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 28, 2026 at 22:58 UTC.

From Beta Bionics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• Our proprietary automated dosing algorithms embedded within the iLet are cleared by FDA as an iAGC.
• We rely on trade secret protection for certain unpatented aspects of other proprietary technology.
• The laws of foreign countries generally do not protect our proprietary rights to the same extent as do the laws of the United States.
• We work with subject matter experts internationally, and our licensing partners to best manage foreign intellectual property matters, with their advice and consent to assure that our business and proprietary data strategies are co-extensive and consistent.

Partnerships

• We granted DexCom a non-exclusive, limited license to use certain of our trademarks in connection with commercialization of the Combined Platform under the Commercialization Agreement.
• Through an exclusive collaboration and license agreement with Xeris Pharmaceuticals (Xeris), we are developing a pump-compatible, shelf-stable glucagon formulation utilizing Xeris' XeriSol technology.

Legal & Regulatory Risks (Item 1A, quoted)

• We and our suppliers are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements.
• The FDA can also publish Safety Communications or Letters to Health Care Providers when the agency becomes aware of new issues involving a specific product or, more broadly, a product family.
• Our iLet or any of its components may be subject to product recalls in the future. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our iLet, could have a significant adverse impact on us.
• Our relationships with HCPs and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to significant penalties, including criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 22:58 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt